Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Joseph Anthony Bilotta

Eric Mertz

Shawn David Erickson

Nancy-Ellen Haynes

Qingjie Ding

Kevin Richard Guertin

Kshitij Chhabilbhai Thakkar

Robert James Weikert

Jefferson Wright Tilley

Yimin Qian

Matthew Michael Hamilton

Sung-Sau So

Jean-Marc Plancher

Alexander Mayweg

Paul Gillespie

Zhi Chen

Fariborz Firooznia

Elbert Chin

Robert Alan Goodnow, Jr

Nader Fotouhi

Sherrie Lynn Pietranico-Cole

Adrian Wai-Hing Cheung

Jing Zhang

Buelent Kocer

Nan Jiang

Nathan Robert Scott

Stephen Deems Gabriel

Lida Qi

Jenny Tan

Agnieszka Kowalczyk

Qiang Zhang

Stuart Hayden

Nicholas Marcopulos

Michael Paul Myers

Bruce Lester Banner

Feng Chi

Han Ma

Christine M Lukacs-Lesburg

Alexander V Mayweg

Robert Alan Goodnow Jr

Klaus Klumpp

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

Antiviral compounds

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Aminomethyl quinolone compounds

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

Pyrazolones as inhibitors of 11&#x3b2;-hydroxysteroid dehydrogenase

Growing community of inventors

Nutley, NJ, United States of America

Joseph Anthony Bilotta